LANTRONIX INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LANTRONIX INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $122.92M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $160.33M | Aug 29, 2025 |
| FY2022 | Jun 30, 2022 | $129.66M | Aug 29, 2022 |
| FY2022 | Jun 30, 2021 | $71.48M | Aug 29, 2022 |
| FY2019 | Jun 30, 2019 | $46.89M | Sep 11, 2019 |
| FY2019 | Jun 30, 2018 | $45.58M | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $44.73M | Aug 23, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $122.92M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $160.33M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $131.19M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $129.66M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $71.48M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $59.88M | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | $46.89M | Sep 11, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $44.73M | Aug 24, 2017 |
| FY2017 | Jun 30, 2016 | $40.59M | Aug 24, 2017 |
| FY2016 | Jun 30, 2015 | $42.95M | Aug 24, 2016 |
| FY2015 | Jun 30, 2014 | $44.55M | Aug 21, 2015 |
| FY2014 | Jun 30, 2013 | $46.66M | Aug 22, 2014 |
| FY2013 | Jun 30, 2012 | $45.38M | Aug 29, 2013 |
| FY2012 | Jun 30, 2011 | $49.32M | Aug 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $51.70M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $64.35M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $56.26M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $55.59M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $33.03M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $26.90M | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | $26.27M | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $25.41M | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $23.58M | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | $19.38M | Aug 24, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($11.37M) | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | ($4.52M) | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | ($8.98M) | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | ($5.36M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | ($4.04M) | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | ($10.74M) | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | ($408.0K) | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $680.0K | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | ($277.0K) | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | ($1.96M) | Aug 24, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($11.00M) | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | ($2.86M) | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | ($6.67M) | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | ($5.01M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | ($3.34M) | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | ($10.54M) | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | ($488.0K) | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $804.0K | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | ($183.0K) | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | ($1.93M) | Aug 24, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $18.60M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $20.28M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $19.63M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $17.69M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $11.11M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $9.69M | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | $9.08M | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $7.75M | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $7.96M | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | $6.91M | Aug 24, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $36.25M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $40.21M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $36.95M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $34.53M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $20.81M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $19.58M | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | $15.85M | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $16.35M | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $15.80M | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | $14.40M | Aug 24, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $7.29M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $18.62M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $237.0K | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | ($9.42M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $4.30M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | ($2.52M) | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | ($1.75M) | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $509.0K | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $2.07M | Aug 23, 2018 |
| FY2013 | Jun 30, 2013 | ($4.48M) | Aug 29, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $505.0K | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $1.48M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $2.67M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $2.12M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $783.0K | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $572.0K | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | $891.0K | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $229.0K | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $236.0K | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | $570.0K | Aug 24, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $123.72M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $136.21M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $151.62M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $137.37M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $72.57M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $67.93M | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | $48.94M | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $33.86M | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $30.13M | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | $27.78M | Aug 24, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $49.34M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $54.85M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $74.07M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $57.48M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $26.47M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $21.41M | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | $11.68M | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $10.04M | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $9.44M | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | $8.06M | Aug 24, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $74.38M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $81.36M | Aug 29, 2025 |
| FY2025 | Jun 30, 2023 | $77.56M | Aug 29, 2025 |
| FY2024 | Jun 30, 2022 | $79.90M | Sep 9, 2024 |
| FY2023 | Jun 30, 2021 | $46.10M | Sep 12, 2023 |
| FY2022 | Jun 30, 2020 | $46.52M | Aug 29, 2022 |
| FY2021 | Jun 30, 2019 | $37.27M | Aug 27, 2021 |
| FY2020 | Jun 30, 2018 | $23.81M | Sep 11, 2020 |
| FY2019 | Jun 30, 2017 | $20.69M | Sep 11, 2019 |
| FY2018 | Jun 30, 2016 | $19.72M | Aug 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $31.09M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $27.82M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $27.82M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $20.77M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $15.81M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $15.81M | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | $9.49M | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | $9.49M | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | $9.49M | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | $9.49M | Aug 24, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($234.39M) | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | ($223.02M) | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | ($218.51M) | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | ($209.53M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | ($204.16M) | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | ($200.12M) | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | ($189.38M) | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | ($189.56M) | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | ($190.24M) | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | ($189.95M) | Aug 24, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $20.10M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | $26.24M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | $13.45M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | $17.22M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $9.74M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | $7.69M | Aug 27, 2021 |
| FY2021 | Jun 30, 2019 | $18.28M | Aug 27, 2021 |
| FY2020 | Jun 30, 2018 | $9.57M | Sep 11, 2020 |
| FY2019 | Jun 30, 2017 | $8.07M | Sep 11, 2019 |
| FY2018 | Jun 30, 2016 | $5.96M | Aug 23, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jun 30, 2020 | $5.25M | Sep 11, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Aug 29, 2022 |
| FY2019 | Jun 30, 2019 | 0 | Sep 11, 2019 |
| FY2019 | Jun 30, 2018 | 0 | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Aug 23, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Aug 29, 2022 |
| FY2019 | Jun 30, 2019 | 0 | Sep 11, 2019 |
| FY2019 | Jun 30, 2018 | 0 | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Aug 23, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 39.10M | Aug 29, 2025 |
| FY2025 | Jun 30, 2024 | 37.87M | Aug 29, 2025 |
| FY2024 | Jun 30, 2023 | 36.88M | Sep 9, 2024 |
| FY2023 | Jun 30, 2022 | 35.13M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | 29.09M | Aug 29, 2022 |
| FY2021 | Jun 30, 2020 | 28.23M | Aug 27, 2021 |
| FY2020 | Jun 30, 2019 | 22.81M | Sep 11, 2020 |
| FY2019 | Jun 30, 2018 | 18.91M | Sep 11, 2019 |
| FY2018 | Jun 30, 2017 | 17.81M | Aug 23, 2018 |
| FY2017 | Jun 30, 2016 | 17.25M | Aug 24, 2017 |